PDF(Pubmed)
Abstract：
The emergence of inflammatory diseases is a heavy burden on modern societies. Cannabis has been used for several millennia to treat inflammatory disorders such as rheumatism or gout. Since the characterization of cannabinoid receptors, CB1 and CB2, the potential of cannabinoid pharmacotherapy in inflammatory conditions has received great interest. Several studies have identified the importance of these receptors in immune cell migration and in the production of inflammatory mediators. As the presence of the CB2 receptor was documented to be more predominant in immune cells, several pharmacological agonists and antagonists have been designed to treat inflammation. To better define the potential of the CB2 receptor, three online databases, PubMed, Google Scholar and clinicaltrial.gov, were searched without language restriction. The full texts of articles presenting data on the endocannabinoid system, the CB2 receptor and its role in modulating inflammation in vitro, in animal models and in the context of clinical trials were reviewed. Finally, we discuss the clinical potential of the latest cannabinoid-based therapies in inflammatory diseases.
摘要：
炎症性疾病的出现是现代社会的沉重负担。大麻已被用于治疗炎症性疾病如风湿病或痛风数千年。由于大麻素受体的表征，CB1和CB2，大麻素药物治疗在炎症中的潜力已经引起了极大的兴趣。一些研究已经确定了这些受体在免疫细胞迁移和炎症介质产生中的重要性。由于CB2受体的存在被证明在免疫细胞中更占优势，已经设计了几种药物激动剂和拮抗剂来治疗炎症。为了更好地定义CB2受体的潜力，三个在线数据库，PubMed,谷歌学者和clinicaltrial.gov，搜索没有语言限制。介绍内源性大麻素系统数据的文章全文，CB2受体及其在体外调节炎症中的作用，在动物模型和临床试验中进行了综述。最后,我们讨论了最新的基于大麻素的疗法在炎症性疾病中的临床潜力。
